特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:前立腺がん - 治療薬の予測と市場分析

Prostate Cancer: Global Drug Forecast and Market Analysis to 2028

発行 GlobalData 商品コード 611827
出版日 ページ情報 英文 212 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
PharmaPoint:前立腺がん - 治療薬の予測と市場分析 Prostate Cancer: Global Drug Forecast and Market Analysis to 2028
出版日: 2019年08月31日 ページ情報: 英文 212 Pages
概要

世界の主要8ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本、中国) における前立腺がんの治療薬市場は、2018年には93億米ドル、2028年には128億米ドルと、3.3%のCAGR (複合年間成長率) で成長する見通しです。

当レポートでは、世界の前立腺がんの治療薬の市場の現状と将来展望について分析し、疾患の概要や今後の疫学的予測、主要企業のプロファイルと代表的製品、市場のアンメットニーズと将来的な機会、現在治験中のパイプライン製品の情報、今後の市場規模と影響要因などを調査しております。

第1章 目次

第2章 前立腺がん:エグゼクティブ・サマリー

第3章 イントロダクション

第4章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • バイオマーカー
  • 病期分類

第5章 疫学

  • 疾患の背景事情
  • リスク要因と共存症
  • 過去の世界的傾向
  • 予測手法
    • 情報源
    • 予測の前提条件と手法
  • 前立腺がんの疫学的予測 (通算11年間分)
    • 受診済み有病者数
    • 受診済み有病者数:年齢別
    • 受診済み有病者数:悪性度 (Gleason Score) 別
    • 受診済み有病者数:診断時の病期別
    • 受診済み有病者数:リスク分類別
    • 診断時の転移件数
    • 診断済みの5年有病者数
    • 診断済みの5年有病者数:ホルモン感受性疾患から去勢抵抗性前立腺がん (CRPC) に進行した事例、病状別
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第6章 疾患の管理

  • 診断・治療の概要
  • 治療の概要
    • 治療ガイドラインと主な処方薬
    • 臨床診療
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国

第7章 市場競争の分析

  • 概要

第8章 アンメットニーズと市場機会の評価

  • 概要
  • 全生存期間 (OS) の持続的な改善効果、または転移性CRPCの治療効果のある治療薬
  • 新たな標的および反応効果予測用バイオマーカーの識別
  • 薬剤耐性の発見・治療に関する成果
  • 非転移性CPRCの治療オプション

第9章 パイプライン評価

  • 概要
  • 治験段階にある将来有望な薬剤

第10章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • Johnson & Johnson
    • アステラス製薬
    • AstraZeneca
    • Bayer
    • Clovis Oncology
    • Merck
    • Novartis
    • Pfizer
    • Roche
    • Sanofi

第11章 市場の将来展望

  • 世界市場
    • 市場予測
    • 促進・阻害要因:世界的課題
  • 米国
    • 市場予測
    • 近年の主な動向
    • 市場促進・阻害要因
  • 欧州主要5ヶ国 (EU5)
  • 日本
  • 中国 (都市部)

第12章 付録

図表

List of Tables

  • Table 1: Prostate Cancer: Key Metrics in Eight Major Pharmaceutical Markets
  • Table 2: Stage Definitions for PCa
  • Table 3: NCCN Risk-Category Classification System for PCa
  • Table 4: Risk Factors and Comorbidities for Prostate Cancer
  • Table 5: AJCC Staging of Prostate Cancer
  • Table 6: Treatment Guidelines for Prostate Cancer
  • Table 7: Country Profile - US
  • Table 8: Country Profile - France
  • Table 9: Country Profile - Germany
  • Table 10: Country Profile - Italy
  • Table 11: Country Profile - Spain
  • Table 12: Country Profile - UK
  • Table 13: Country Profile - Japan
  • Table 14: Country Profile - China
  • Table 15: Leading Branded Treatment for PCa, 2019
  • Table 16: Key Companies in the PCa Market in the 8MM, 2018-2028
  • Table 17: J&J's PCa Portfolio Assessment, 2019
  • Table 18: Astellas' PCa Portfolio Assessment, 2019
  • Table 19: AstraZeneca's PCa Portfolio Assessment, 2019
  • Table 20: Bayer's PCa Portfolio Assessment, 2019
  • Table 21: Clovis Oncology's PCa Portfolio Assessment, 2019
  • Table 22: Merck's PCa Portfolio Assessment, 2019
  • Table 23: Novartis' PCa Portfolio Assessment, 2019
  • Table 24: Pfizer's PCa Portfolio Assessment, 2019
  • Table 25: Roche's PCa Portfolio Assessment, 2019
  • Table 26: Sanofi's PCa Portfolio Assessment, 2019
  • Table 27: Prostate Cancer Market - Global Drivers and Barriers, 2018-2028
  • Table 28: Key Events Impacting Sales for Prostate Cancer in the US, 2018-2028
  • Table 29: Prostate Cancer Market -Drivers and Barriers in the US, 2018-2028
  • Table 30: Key Events Impacting Sales for Prostate Cancer in the 5EU, 2018-2028
  • Table 31: Prostate Cancer Market - Drivers and Barriers in the 5EU, 2018-2028
  • Table 32: Prostate Cancer Market in the 5EU - Country-Specific Barriers in the 5EU, 2018-2028
  • Table 33: Key Events Impacting Sales for Prostate Cancer in Japan, 2018-2028
  • Table 34: Prostate Cancer Market - Drivers and Barriers in Japan, 2018-2028
  • Table 35: Key Events Impacting Sales for Prostate Cancer in China, 2018-2028
  • Table 36: Prostate Cancer Market - Drivers and Barriers in China, 2018-2028
  • Table 37: Key Historical and Projected Launch Dates for Prostate Cancer
  • Table 38: Key Projected Patent Expiry/Market Exclusivity Dates for Prostate Cancer
  • Table 39: Average Body BSA Across the 8MM
  • Table 40: High-Prescribing Physicians (non-KOLs) Surveyed, by Country and Specialty

List of Figures

  • Figure 1: Global Sales Forecast by Country for Prostate Cancer in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in Prostate Cancer During the Forecast Period, 2018-2028
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents in Prostate Cancer, 2018-2028
  • Figure 4: 8MM, Diagnosed Incidence of Prostate Cancer, Men, Ages ≥30 Years, 2008-2028
  • Figure 5: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer
  • Figure 6: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores
  • Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
  • Figure 8: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Risk Category
  • Figure 9: 8MM, Sources Used, Metastatic Cases at Diagnosis
  • Figure 10: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer
  • Figure 11: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC
  • Figure 12: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC by Status
  • Figure 13: 8MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018
  • Figure 14: 8MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, Men, N, 2018
  • Figure 15: 8MM, Diagnosed Incident Cases of Prostate Cancer by Gleason Score, Ages ≥30 Years, Men, N, 2018
  • Figure 16: 8MM, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis, Ages ≥30 Years, Men, N, 2018
  • Figure 17: 8MM, Diagnosed Incident Cases of Prostate Cancer by Risk Category, Ages ≥30 Years, Men, N, 2018
  • Figure 18: 8MM, Metastatic Cases at Diagnosis, Ages ≥30 Years, Men, N, 2018
  • Figure 19: 8MM, Five-Year Diagnosed Prevalent Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018
  • Figure 20: 8MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status, Ages ≥30 Years, Men, N, 2018
  • Figure 21: Treatment Algorithm for Localized Prostate Cancer
  • Figure 22: Treatment Algorithm for Progressive and Advanced Prostate Cancer
  • Figure 23: Overview of the Unmet Need and Opportunity in Prostate Cancer, 2019
  • Figure 24: Overview of the Development Pipeline in PCa
  • Figure 25: Pivotal Phase II/III Trials for the Promising PCa Pipeline Agents
  • Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of PCa During the Forecast Period
  • Figure 27: Analysis of the Company Portfolio Gap in PCa During the Forecast Period
  • Figure 28: Global (8MM) Sales Forecast by Country for Prostate Cancer in 2018 and 2028
  • Figure 29: Global (8MM) Sales Forecast by Drug Class for Prostate Cancer in 2018 and 2028
  • Figure 30: Sales Forecast by Class for Prostate Cancer in the US in 2018 and 2028
  • Figure 31: Sales Forecast by Class for Prostate Cancer in the 5EU in 2018 and 2028
  • Figure 32: Sales Forecast by Class for Prostate Cancer in Japan in 2018 and 2028
  • Figure 33: Sales Forecast by Class for Prostate Cancer in China in 2018 and 2028
目次
Product Code: GDHC162PIDR

The prostate cancer market will undergo a moderate increase at a compound annual growth rate (CAGR) of 3.3% from an estimated $9.3bn in 2018 to $12.8bn in 2028 in the eight major markets (8MM - US, France, Germany, Italy, Spain, UK, Japan and China. The main drivers of growth will be an aging population, continued uptake of second-generation hormonal agents in the metastatic hormone naive (mHNPC) and non-metastatic castration resistant (nmCRPC) prostate cancer settings, and the launch and uptake of 13 new premium-priced therapies, including the newly approved Nubeqa (darolutamide).

Of these, the biggest driver of growth is the expansion of second-generation hormonal agents into metastatic hormone-naive prostate cancer (mHNPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC), which will bring these expensive drugs into earlier lines of therapy.

This will doubly impact market growth, as the shifting paradigm will create space in the metastatic castration-resistant prostate cancer (mCRPC) space, where these agents once reigned, allowing pipeline agents a chance to gain substantial market share and fill this void.

Second-generation hormonal therapies Johnson & Johnson's Zytiga (abiraterone acetate) and Erleada (apalutamide), Astellas/Pfizer's Xtandi (enzalutamide) and Bayer/Orion's Nubeqa (darolutamide) have been racing to acquire approvals and label expansions over the past couple years.

Between 2018 and 2019, three of these agents gained approval in nmCRPC. Zytiga gained a label expansion for metastatic hormone-naive prostate cancer (mHNPC) in 2017 for the EU and in 2018 for the US, while the other three agents are soon to follow. J&J filed for US Food and Drug Administration (FDA) approval of Erleada in mHNPC in April 2019, and Xtandi was given an FDA priority review in August.

The report "Prostate Cancer: Global Drug Forecast and Market Analysis to 2028" provides an overview of the risk factors, comorbidities, and global and historical trends for prostate cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).

Scope

  • Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2018 to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Prostate Cancer: Executive Summary

  • 2.1 Prostate Cancer Market Expected to Increase Despite Generic Abiraterone Entry
  • 2.2 Big Pharma Brands Enter the Prostate Cancer Market Using Combination Strategies for mCRPC
  • 2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response
  • 2.4 Prostate Cancer Pipeline Moving Towards Precision Medicine
  • 2.5 What Do the Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
    • 4.1.3 Biomarkers
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods, Population
    • 5.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer
    • 5.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores
    • 5.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
    • 5.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Risk Category
    • 5.4.7 Forecast Assumptions and Methods, Metastatic Cases at Diagnosis
    • 5.4.8 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Prostate Cancer
    • 5.4.9 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases (Metastatic and Non-Metastatic) that Progress from Hormone-Sensitive Disease to CRPC by Status
  • 5.5 Epidemiological Forecast for Prostate Cancer (2018-2028)
    • 5.5.1 Diagnosed Incident Cases of Prostate Cancer
    • 5.5.2 Age-Specific Incident Cases of Prostate Cancer
    • 5.5.3 Diagnosed Incident Cases of Prostate Cancer by Gleason Score
    • 5.5.4 Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
    • 5.5.5 Diagnosed Incident Cases of Prostate Cancer by Risk Category
    • 5.5.6 Metastatic Cases at Diagnosis
    • 5.5.7 Five-Year Diagnosed Prevalent Cases of Prostate Cancer
    • 5.5.8 Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of Analysis
    • 5.6.3 Strengths of Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 Treatment Overview
    • 6.2.1 Treatment Guidelines and Leading Prescribed Drugs
    • 6.2.2 Clinical Practice
  • 6.3 US
  • 6.4 France
  • 6.5 Germany
  • 6.6 Italy
  • 6.7 Spain
  • 6.8 UK
  • 6.9 Japan
  • 6.10 China

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Therapies with a Durable OS Benefit or Cure for mCRPC
  • 8.3 Identification of New Targets and Positive Predictive Biomarkers of Response
  • 8.4 Advancements in the Detection and Treatment of Drug Resistance
  • 8.5 Therapeutic Options for nmCRPC

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 Company Profiles
    • 10.3.1 Johnson & Johnson
    • 10.3.2 Astellas
    • 10.3.3 AstraZeneca
    • 10.3.4 Bayer
    • 10.3.5 Clovis Oncology
    • 10.3.6 Merck
    • 10.3.7 Novartis
    • 10.3.8 Pfizer
    • 10.3.9 Roche
    • 10.3.10 Sanofi

11 Market Outlook

  • 11.1 Global Markets
    • 11.1.1 Forecast
    • 11.1.2 Drivers and Barriers - Global Issues
  • 11.2 US
    • 11.2.1 Forecast
    • 11.2.2 Key Events
    • 11.2.3 Drivers and Barriers
  • 11.3 5EU
    • 11.3.1 Forecast
    • 11.3.2 Key Events
    • 11.3.3 Drivers and Barriers
  • 11.4 Japan
    • 11.4.1 Forecast
    • 11.4.2 Key Events
    • 11.4.3 Drivers and Barriers
  • 11.5 China (Urban)
    • 11.5.1 Forecast
    • 11.5.2 Key Events
    • 11.5.3 Drivers and Barriers

12 Appendix